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Introduction: Liver transplantation (LT) can result in significant bleeding
requiring transfusion of allogenic blood products, which potentially leads to
postoperative morbidity and mortality (1). This study aimed to determine
transfusion needs during LT in our institution and its preoperative predictive
factors.
Material and Methods: Two hundred LT performed at the CHU Liege
between 2006 and 2012 were respectively reviewed (age = 55 ! 11 yo,
BMI = 25.5 ! 4.4 kg/m2, F/M = 45/155, MELD score = 19 ! 10). Transfu-
sion needs of the different blood products during POD 0, and POD 0–7 were
recorded. Parameters associated with the transfusion of more than 2 units of
RBC (p ≤ 0.1) were identified using the Kruskal Wallis and chi square tests
(table 1). These parameters were then placed into a backward stepwise logistic
regression model for the transfusion of more than two units of RBC at POD 0. A
p value threshold ≥0.1 was used for leaving the model.
Results: Transfusion needs were: RBC = 2[0–4], FFP = 4[2–7], PLT = 1[0–
1] during POD 0; and RBC = 3[0–6], FFP = 6[3–10], PLT = 1[0–2] during POD
0–7. Preoperative factors independently associated with the transfusion of
more than two units of RBC were preop Hb (0.6 [0.46–0.79], p < 0.001) and
MELD score (1.13 [1.06–1.20], p < 0.001).
Discussion: These results suggest that preop Hb and MELD score are
associated with blood requirements during LT.
References: 1. J Am Coll Surg 2013; 216:902–7.
Table 1 Data are median [IQR].
>2 RBCs ≤2 RBCs p value
Female gender, % 73 78 0.5
BMI, kg/m2 24.8 [5.3] 25 [4] 0.6
NHBD donor, % 18 42 0.001
Portal hypertension, % 53 49 0.6
Cold ischemia time, min 321 [23] 286 [294] 0.38
Warm ischemia time, min 41 [14] 44 [15] 0.2
MELD score 27 [8] 14 [10] <0.001
Preop Hb, g/dl 10 [3] 12.5 [3] <0.001
Preop fibrinogen, g/l 1.9 [2.1] 2.8 [1.5] <0.001
Preop platelets, 91003/ll 79 [52] 95 [76] 0.03
NHBD, Non-heart-beating donor; MELD, Model for End-Stage Liver
Disease score.
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Introduction: We designed a retrospective observational study to evaluate
everolimus usage ab initio after liver transplantation.
Materials and Methods: Fifty five non consecutive adult patients (47M/8F,
mean age 52 ! 10.5 years) who received liver transplantation between 2009
and 2014 were included in the study. All recipients received everolimus from
the first transplant day either in association with CNI’s or antimetabolites. The
primary goal was to assess the safety and feasibility of everolimus after liver
transplantation; the remaining objectives were to evaluate liver function and the
incidence of rejection and side effects. Results: The 1 year patient and graft
survival was 85%. Liver function was stable during the follow-up of 1 year. No
rejections were observed. Only five patients (12%) required therapy for onset
dyslipidaemia. Conclusion: Low-dose regimen of everolimus immediately after
liver transplantation is safe and feasible when!ı associated with low doses of
calcineurin-inhibitor or antimetabolite, permitting to avoid all the side effects of
standard regimens with higher doses.
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Objectives: Despite progress in medical management, classical maple syrup
urine disease (MSUD) poses a risk of serious neurologic disability and untimely
death. Acute metabolic intoxication causes cerebral edema that can culminate
in brain herniation and cardiorespiratory arrest. We represent early post
transplant period of two pediatric MSUD patients whose Branched-chain
ketoacid dehydrogenase (BCKDH) enzyme activity was 0%.
Cases: 28 and 11 months old male patients developed neurologic symptoms
such as nausea, vomiting and drowsiness after birth. Branched-chain amino
asid (BCAA) levels were found high after metabolic evaluation. Patients were
fed with special MSUD formulas because of entire body BCKDH activity was
0%. Thus especially the brain was preserved from acute and chronic metabolic
intoxication. Physical development of patients became appropriate for liver
transplantation. In case 1 living donor liver transplantation (LDLT) was
performed from his father in December 2013. In case 2 LDLT was performed
from his mother in December 2014. Both patients post operative period was
uneventfull. In follow up after transplantation BCAA levels and liver function
tests were normalized in both patients. Three weeks after transplantation
patients were fed entirely normally. Irregularities observed in neurocognitive
functions prior to transplant have disappeared completely at the post transplant
period.
Conclusions: Diatery regulation is mandotary for MSUD. Particularly in
developing countries, the availability of medical foods, convenience and speed
of amino acid monitoring, and access to emergency metabolic care is still a
major problem. Therefore, Liver transplantation is an effective alternative to
dietary treatment in patients with MSUD. Liver transplantation provides
sufficient BCKDH enzyme activity so it can be effective and permanent method
for treatment of this disease. And also liver transplantation may prevent
possible brain damage in these patients.
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